Clinical Trials Directory

Trials / Unknown

UnknownNCT04053296

Long-term Outcomes of Pregnant Women With PAH

Morbidity and Outcomes of Pregnant Women With Pulmonary Arterial Hypertension During Different Pregnancies

Status
Unknown
Phase
Study type
Observational
Enrollment
120 (estimated)
Sponsor
RenJi Hospital · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Accepted

Summary

The investigators intend to explore the characteristics and outcomes of pregnant women with PAH during different pregnancies and to provide applicable evidence for clinical practice.

Detailed description

Pulmonary arterial hypertension (PAH) is a fatal disease with progressive vascular resistance that leads to the loss of right heart function. Avoiding pregnancy is essential for PAH women. In recent years, maternal mortality in pregnant women with PAH has decreased mostly due to emerging advanced therapies for PAH and the progress in high-risk pregnancy management. Nevertheless, the maternal death rate in parturients with PAH remains high; therefore, contraception is still recommended for women diagnosed with PAH. However, some women develop this condition during pregnancy. With the two-child policy, families in China are allowed to have a second child. As a result, the number of PAH diagnoses during pregnancy may increase with the general increase in the number of pregnant women. Additionally, some patients develop PAH only during their second pregnancy. In order to investigate the incidence and clinical characteristics of pregnant women diagnosed with PAH during different pregnancies, this observational study aimed to analyze perinatal and pregnancy clinical data, to compare the perinatal status and maternal and infant outcomes of the first and second pregnancies complicated with PAH, establishing a clinical basis for the prenatal consultation, diagnosis, and treatment of pregnant women with PAH.

Conditions

Interventions

TypeNameDescription
OTHERObservational studyWe follow up the results of patients.

Timeline

Start date
2017-11-01
Primary completion
2019-12-31
Completion
2019-12-31
First posted
2019-08-12
Last updated
2019-08-12

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04053296. Inclusion in this directory is not an endorsement.